{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134805","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.379492+00:00","generated_at":"2026-06-02T07:19:37.292466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CG Oncology reports Q1 net loss $16.9M; cash $566.5M; cretostimogene 75.2% CR rate in BCG-unresponsive NMIBC","bullets":["Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).","Cash and securities $566.5M as of Mar 31, 2024, compared to $187.7M at Dec 31, 2023; runway sufficient through 2027.","Cretostimogene monotherapy achieved 75.2% complete response (79/105) in BOND-003 Phase 3 trial in BCG-unresponsive HR-NMIBC.","Completed oversubscribed $437M IPO in 2024; first Pt dosed in PIVOT-006 Phase 3; CORE-001 combo data to be presented at ASCO June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134805","json":"https://secwatch.observer/filing/0001193125-24-134805.json","markdown":"https://secwatch.observer/filing/0001193125-24-134805.md","text":"https://secwatch.observer/filing/0001193125-24-134805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/0001193125-24-134805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/d774503d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:19:37.292466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5ef2ef22279316280798d8785a0bf52b54151b0","claim":"CG Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income $16.9 million, or ($0.36) per share, EPS ($0.36) per share.","evidence_excerpt":"CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524134805/0001193125-24-134805-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$16.9 million, or ($0.36) per share"},{"label":"EPS","value":"($0.36) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}